LRRK2 Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.
Report Highlights
This segment of the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs
Further product details are provided in the report……..
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs.
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor R&D. The therapies under development are focused on novel approaches for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor.
This segment of the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs
- ION859: Ionis Pharmaceuticals
- DNL151: Denali Therapeutics
Further product details are provided in the report……..
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs.
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Insights
- Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs?
- How many Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ionis Pharmaceuticals
- Denali Therapeutics
- Neuron23
- Voronoi
- E-Scape Bio
- ION859
- DNL151
- Small molecule therapeutics
- VRN-01
- ESB-5070
Introduction
Executive Summary
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ION859: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
DNL151: Denali Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Leucine-rich repeat kinase 2 inhibitor: Cerevel therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key Companies
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key Products
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Unmet Needs
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Market Drivers and Barriers
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Future Perspectives and Conclusion
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Analyst Views
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key Companies
Appendix
Executive Summary
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ION859: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
DNL151: Denali Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Leucine-rich repeat kinase 2 inhibitor: Cerevel therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key Companies
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key Products
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Unmet Needs
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Market Drivers and Barriers
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Future Perspectives and Conclusion
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Analyst Views
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
